Activation of antitumor immune responses by Ganoderma formosanum polysaccharides in tumor-bearing mice
Journal
Applied Microbiology and Biotechnology
Journal Volume
98
Journal Issue
22
Pages
9389-9398
Date Issued
2014
Author(s)
Abstract
Fungi of the genus Ganoderma are basidiomycetes that have been used as traditional medicine in Asia and have been shown to exhibit various pharmacological activities. We recently found that PS-F2, a polysaccharide fraction purified from the submerged culture broth of Ganoderma formosanum, stimulates the maturation of dendritic cells and primes a T helper 1 (Th1)-polarized adaptive immune response in vivo. In this study, we investigated whether the immune adjuvant function of PS-F2 can stimulate antitumor immune responses in tumor-bearing mice. Continuous intraperitoneal or oral administration of PS-F2 effectively suppressed the growth of colon 26 (C26) adenocarcinoma, B16 melanoma, and sarcoma 180 (S180) tumor cells in mice without adverse effects on the animals’ health. PS-F2 did not cause direct cytotoxicity on tumor cells, and it lost the antitumor effect in mice with severe combined immunodeficiency (SCID). CD4+ T cells, CD8+ T cells, and serum from PS-F2-treated tumor-bearing mice all exhibited antitumor activities when adoptively transferred to na?ve animals, indicating that PS-F2 treatment stimulates tumor-specific cellular and humoral immune responses. These data demonstrate that continuous administration of G. formosanum polysaccharide PS-F2 can activate host immune responses against ongoing tumor growth, suggesting that PS-F2 can potentially be developed into a preventive/therapeutic agent for cancer immunotherapy. ? 2014, Springer-Verlag Berlin Heidelberg.
Subjects
Antitumor; Ganoderma formosanum; Immunomodulation; Polysaccharides
SDGs
Other Subjects
Cytology; Fungi; Immune system; Mammals; Polysaccharides; Tumors; Adaptive immune response; Anti-tumor activities; Anti-tumors; Ganoderma; Humoral immune response; Immuno modulations; Pharmacological activity; Severe combined immunodeficiencies; T-cells; antineoplastic agent; fungal polysaccharide; immunological adjuvant; ps f2; unclassified drug; fungal polysaccharide; immunologic factor; bioassay; cancer; fungus; immune response; medicine; polysaccharide; rodent; toxicity; tumor; adenocarcinoma cell line; adoptive transfer; animal cell; animal experiment; animal model; antineoplastic activity; Article; cancer immunotherapy; cancer inhibition; cancer prevention; CD4+ T lymphocyte; CD8+ T lymphocyte; cell maturation; cellular immunity; continuous infusion; controlled study; dendritic cell; drug cytotoxicity; experimental neoplasm; experimental sarcoma; fungus culture; Ganoderma; Ganoderma formosanum; humoral immunity; immunoreactivity; in vivo study; male; melanoma B16; melanoma cell line; mouse; nonhuman; sarcoma 180; sarcoma cell line; severe combined immunodeficiency; T lymphocyte activation; Th1 cell; treatment indication; animal; disease model; Ganoderma; immunotherapy; isolation and purification; metabolism; Neoplasms; procedures; treatment outcome; Asia; Animalia; Basidiomycota; Fungi; Ganoderma; Ganoderma formosanum; Mus; Animals; Disease Models, Animal; Fungal Polysaccharides; Ganoderma; Immunologic Factors; Immunotherapy; Mice; Neoplasms; Treatment Outcome
Type
journal article